BioPorto A/S (CPH:BIOPOR) (FRA:2P4) CEO Peter Mørch Eriksen tells Proactive the group is slowly starting to see the pandemic 'lifting its burden' as the group sees a 'huge increase' in sales of its antibodies side of the business, along with "good, and steady" sales of its NGAL TesT for its first quarter in 2021.
Eriksen also explained why he recently announced his upcoming departure from the firm as CEO, after spending 8 years at the group.